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Diffusion tensor imaging (DTI) has shown poorer microstructural white matter integrity in children with
phenylketonuria (PKU), speciﬁcally decreases in mean diffusivity (MD), in comparison with healthy children.
However, little research has been conducted to investigate the relationship between age and white matter
integrity in this population. The present study examined group differences in the relationship between age
and MD across a range of brain regions in 31 children with early- and continuously-treated PKU and 51 healthy
control children. Relationships amongMD, age, and groupwere explored using hierarchical linear regression and
Pearson correlation. Results indicated a stronger age-related decrease inMD for childrenwith PKU in comparison
with healthy children in 4 of the 10 brain regions examined, suggesting that the trajectory of white matter
development is abnormal in children with PKU. Further research using longitudinal methodology is needed to
fully elucidate our understanding of white matter development in children with PKU.









Phenylketonuria (PKU1) is an autosomal recessive metabolic disor-
der characterized by a dysfunctional or absent enzyme, phenylalanine
hydroxylase (PAH), which is responsible for the metabolism of the
amino acid phenylalanine (Phe). With little to no functional PAH, Phe
accumulates in the blood and brain of individuals with PKU [1]. Dietary
restriction of foods high in Phe (i.e., high protein foods) such as beans,
dairy products, and meats is necessary to maintain Phe levels within
clinically recommended ranges. To maintain adequate protein require-
ments, the PKU diet is supplemented with drinkable Phe-free formulas.
If untreated, PKU typically has devastating consequences, including
severe intellectual disability [2,3]. Widespread newborn screening
programs implemented in the 1960s largely eradicated the incidence
of untreated cases in developed nations. However, even when PKU
is diagnosed early and treated continuously, affected individuals
demonstrate poorer psychosocial functioning, academic achievement,
and psychiatric outcomes compared with the general population
[4–6]. In addition, individuals with early- and continuously-treated
PKU exhibit slightly lowered IQ [7] and subtle cognitive deﬁcits, partic-
ularly in processing speed [8] and executive abilities such as working
memory, inhibitory control, and strategic processing [9,10]. Recent
work has demonstrated that both elevated Phe levels and greater
variability in Phe levels are associated with poorer IQ and executive
performance in the early- and continuously-treated PKUpopulation [11].
In terms of brain mechanisms that may underlie PKU-related
deﬁcits, a deﬁciency in the neurotransmitter dopamine has long been
hypothesized as a primary factor [1]. In healthy individuals, the action
of PAH converts Phe to tyrosine, which is a precursor of dopamine and
other catecholaminergic neurotransmitters. When this metabolic
pathway is disrupted in individuals with PKU, lower levels of dopamine
are observed [12]. Dopaminergic projections to the prefrontal cortex
are crucial to a number of frontally-mediated, higher-order abilities, in-
cluding working memory, inhibitory control, attention, and cognitive
ﬂexibility [13,14]. It is likely that the impact of reduced dopamine on
this cognitive skill set contributes to the poorer functional outcomes
observed in individuals with early- and continuously-treated PKU.
Of particular relevance to the current study, PKU research has in-
creasingly investigated the white matter of the brain, which facilitates
the efﬁcient ﬂow of neural signals among interconnected brain regions.
Past studies using structural magnetic resonance imaging (MRI) have
identiﬁed decreased white matter volume and hyperintensities in the
white matter that primarily occur in periventricular brain regions
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[15–19]. This structural imaging approach, however, is not ideal for
studying individuals with early- and continuously-treated PKU, because
gross white matter abnormalities are observed less frequently than in
less rigorously treated individuals. In addition, themajority of structural
MRI studies have used a qualitative approach to categorize rather than
quantify white matter abnormalities.
In recent years, diffusion tensor imaging (DTI) has been used as a
quantitative MRI approach to investigate white matter pathology in
individuals with PKU [20–23]. DTI provides information regarding the
microstructural integrity and organization of the white matter by
measuring the movement, or diffusion, of water molecules [24,25].
Two DTI measures are frequently reported: fractional anisotropy (FA)
which reﬂects the degree of asymmetry of water diffusion and mean
diffusivity (MD) which reﬂects the overall spatial average rate of
water diffusion.
In studies of individuals with PKU, normal FA but reduced MD has
been reported consistently [20–22,25–29], suggesting restricted
diffusion within axons. Reduced MD in individuals with early- and
continuously-treated PKU has been associated with both higher blood
Phe levels and increased variability in blood Phe levels [28].With regard
to cognition, reduced MD has also been associated with lower IQ and
poorer performance on executive tasks [20].
From a developmental perspective, there is limited information re-
garding the relationship between age and MD in individuals with PKU.
In healthy children, a sharp increase in MD is typically observed in the
months after birth, followed by a decrease in MD until middle child-
hood, at which time a plateau is generally reached and maintained
until the elderly stages of life [30–32]. With regard to PKU, one study
showed an age-related decrease inMD in anterior regions of the corpus
callosum in childrenwith early- and continuously-treated PKU [22], but
this is the only DTI study to date in which white matter integrity has
been examined from a developmental perspective.
The present study was conducted to more thoroughly investigate
the relationship between age and MD in children with early- and
continuously-treated PKU across a range of brain regions. We hypothe-
sized that increasing age would be more strongly associated with
decreasing MD in children with PKU compared with healthy control
children. To investigate this hypothesis, we examined MD in relation
to age across 10 brain regions of interest (ROI) in school-aged children
with early- and continuously-treated PKU and demographically
matched healthy control children.
2. Materials and methods
2.1. Participants
Participants were children with PKU (n=31; 16 girls, 15 boys) and
healthy control children (n= 51; 26 girls, 25 boys) recruited from the
St. Louis and Portland communities in conjunction with a longitudinal
study funded by the National Institute of Child Health and Human
Development (R01 HD0449901). Children with PKU were recruited
through metabolic clinics at Washington University (WU) and Oregon
Health & Science University (OHSU). All children with PKU were diag-
nosed soon after birth and received early and continuous treatment
through dietary restriction of Phe intake. Average Phe levels over the
year prior to evaluation were provided by referring metabolic clinics
and ranged from 230 to 1574 μmol/L (M = 530.2, SD = 334.9). Phe
levels obtained closest to time of evaluation (i.e., within approximately
onemonth) ranged from 121 to 1574 μmol/L (M= 553.8, SD= 348.5).
There was a signiﬁcant positive correlation between Phe levels closest
to time of evaluation and age, such that Phe levels increased as a
function of increasing age (r= 0.60, p b 0.01).
The age of children in both groups ranged from 7 to 18 years (PKU:
M = 12.2, SD = 3.9; Control: M = 12.0, SD = 3.3). Education ranged
from 1 to 13 years for the PKU group (M = 6.4, SD = 3.6) and 1 to
14 years for the control group (M= 6.2, SD = 3.4). IQ ranged from 86
to 139 for the PKU group (M = 106.8 SD = 11.3) and 84 to 143 for
the control group (M = 115.2, SD = 14.8). Chi square and t-test
analyses revealed no signiﬁcant between-group differences in gender,
age, or education (p N 0.05 in all instances), but IQ was signiﬁcantly
lower for the PKU than control group (p b 0.01). No child had a history
of intellectual disability, learning disorder, or major medical disorder
unrelated to PKU.
2.2. Procedures
Approval to conduct the study was obtained from Human Research
Protection Ofﬁces at WU and OHSU. Informed consent and assent
were obtained from all guardians and participants before administra-
tion of any study procedures. A cognitive battery was administered as
part of a larger study, but ﬁndings from only measures of relevance to
the current study are reported here. Cognitive testing andneuroimaging
procedures were administered during a single session lasting approxi-
mately 4 h. Findings from neuroimaging procedures have been previ-
ously reported [22], but not in relation to age across multiple ROIs.
2.3. Neuroimaging
Neuroimaging procedures are reported in greater detail elsewhere
[22]. Brieﬂy, structural images were acquired using a Siemens Sonata
1.5T system at WU and a Siemens TIM Trio 3.0T system at OHSU. Of
the 31 children with PKU, 15 were imaged at WU and 16 at OHSU. Of
the 51 control subjects, 48were imaged atWU and 3 at OHSU. Although
different proportions of children in the PKU and control groups were
imaged at WU versus OHSU, the pattern of results did not change
when imaging site was controlled in analyses. Similarly, the pattern of
results did not change when gender was controlled in analyses. As
such, the reported analyses include neither imaging site nor gender.
Scans included a T1-weighted (T1W) sagittal, magnetization-
prepared rapid gradient echo (MPRAGE) and a T2-weighted (T2W)
fast spin echo. DTIwas acquired using an echo planar imaging sequence
[2.5mm (OHSU) and 3.0mm(WU) isotropic voxels, diffusion sensitiza-
tion of b-values = 0 and 1000 s/mm2] along 25 non-collinear diffusion
gradient orientations. Diffusion weighted images were registered ﬁrst
to the b = 0 unsensitized image, then to the T2W, then to the best
T1W (MPRAGE), and ﬁnally to a WU in-house atlas. T2W images were
visually inspected to ensure that measurements were acquired from
normal-appearing white matter without hyperintensities.
MD analyses were conducted across 10 ROIs, including: prefrontal
cortex, centrum semiovale, posterior parietal-occipital cortex, optic
radiation, putamen, thalamus, hippocampus, and the genu, body, and
splenium of the corpus callosum (CC). These regions were selected
based on a well-established DTI atlas [33] to provide a sampling of
white matter tracts across the brain and were veriﬁed by a neuroradiol-
ogist. We chose to perform ROI analyses rather than undertake a voxel-
wise approach to minimize type 1 error due to multiple comparisons
and to avoid imperfect smoothing effects [34]. Furthermore, previous
research has indicated no observable difference between the use of
ROI versus voxel-based analyses when examining mean diffusivity in
children [35].
The diffusion tensor and its three eigenvalues were calculated using
log-linear regression in each voxel for each ROI. Using standard
methods, MD was computed as the average of the three eigenvalues,
and a parametric map was then generated for MD. ROIs were then
applied to each participant's MD parametric map and sampled using
Analyze version 8.0 (Mayo Clinic, Rochester). Values from left and
right homologous regions were averaged.
2.4. Statistical analyses
Hierarchical linear regression analyses were performed to deter-
mine the proportion of variance in MD for each ROI that was
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attributable to age, group, and the interaction between age and group.
Age was entered in the ﬁrst step, followed by group (PKU, control),
followed by the age by group interaction. The interaction between age
and groupwas of particular interest in terms evaluatingwhether the re-
lationship between age and MD differed for PKU and control groups.
Pearson correlations between age andMD for each groupwere then ob-
tained to further explore signiﬁcant age by group interactions revealed
by linear regression. Because the sampling distribution of correlations
was not normally distributed (ρ ≠ 0), Fisher R → Z transformations
were conducted for each correlation. A z-test of signiﬁcance was used
with the resulting statistics to determine whether the correlation be-
tween age and MD signiﬁcantly differed between the PKU and control
groups. Between-group differences were considered signiﬁcant if
p b 0.05 (i.e., z b−1.96).
3. Results
The mean and standard deviation of MD for each ROI are listed in
Table 1. Statistical ﬁndings from hierarchical linear regression analyses
examining the relationships between MD in the 10 ROIs and age,
group, and the interaction between age and group are reported in
Table 2. Age accounted for a signiﬁcant proportion of the variance in
MD across all ROIs except the genu of the CC. After considering the
variance attributable to age, group accounted for a signiﬁcant propor-
tion of the variance in MD for the genu of the CC, centrum semiovale,
posterior parietal-occipital cortex, hippocampus, and thalamus. Of
particular interest, the interaction between age and group accounted
for a signiﬁcant proportion of the variance in MD for the splenium and
genu of the CC, the optic radiation, and the hippocampus, indicating a
differential effect of age on MD for the PKU and control groups.
Correlation analyses were used to further explore the signiﬁcant in-
teractions between age and group. As shown in Table 3, for the control
group there were no signiﬁcant correlations between age and MD in
any of the 4 ROIs examined, although for the PKU group all correlations
between age andMDwere signiﬁcantwithmediumor large effect sizes.
In terms of between-group differences, the correlation between age and
MD was signiﬁcantly different (z b −1.96) between the PKU and
control groups for the genu of the CC, optic radiation, and hippocampus;
although no signiﬁcant between-groupdifference in the correlationwas
found for the splenium, the correlation trended in the same direction as
for the other ROIs. Overall, these results indicate that MD decreased as a
function of increasing age for the PKU group but not the control group.
4. Discussion
Subtle cognitive compromise in childrenwith early-and continuously-
treated PKU has been associated with both gross structural [15–19] and
microstructural [20–23] white matter abnormalities in the brain. Of
particular relevance to the current research, a number of studies have
shown that MD across a range of brain regions is lower in children with
early- and continuously-treated PKU in comparisonwith healthy controls
[20–22,25–29], but little is known about the developmental trajectory of
MD in this population. As such, the current studywas conducted to assess
whether the relationship between age and MD was different between
children with PKU and healthy control children.
Results from hierarchical linear regression analyses provided
evidence that the relationship between age and MD differed between
these groups. Speciﬁcally, after considering the variance attributable
to age and group, the interaction between age and group accounted
for a signiﬁcant proportion of the variance in MD for the splenium and
genu of the CC, optic radiation, and hippocampus. Further correlation
analyses showed that, in these four ROIs, MD decreased as a function
of increasing age for the PKU group but not the control group. In turn,
these ﬁndings appear to be associated with the age-related increase in
Phe levels in children with PKU, because the age-related DTI ﬁndings
were no longer signiﬁcant after Phe levels were controlled in analyses.
Overall, these ﬁndings suggest that worsening metabolic control with
age may underlie worsening microstructural white matter integrity as
children with PKU age.
It is interesting to consider the speciﬁc brain regions in which age-
related decreases in MD were observed for the PKU group. Turning
ﬁrst to the optic radiation, although few human studies have been
conducted on the development of this white matter tract, the available
Table 3
Correlations and between-group differences in correlations between age and MD for the
PKU and control groups.




Splenium of the CC −0.17 −0.51⁎ −1.64
Genu of the CC 0.10 −0.49⁎ −2.68⁎
Optic radiation −0.11 −0.55⁎ −2.13⁎
Hippocampus −0.21 −0.62⁎ −2.17⁎
⁎ p b 0.05.
Table 2
Statistical ﬁndings from hierarchical linear regression analyses examining the variance in MD attributable to age, group, and the age × group interaction.
ROI Age Group Age × Group
R2 F p ΔR2 ΔF p ΔR2 ΔF p
Splenium of the CC 0.12 10.61 0.01⁎ 0.00 0.00 0.97 0.05 4.22 0.04⁎
Genu of the CC 0.04 2.90 0.09 0.07 6.47 0.01⁎ 0.09 8.44 0.01⁎
Body of the CC 0.20 19.38 0.01⁎ 0.02 1.65 0.20 0.00 0.09 0.77
Optic radiation 0.11 10.25 0.01⁎ 0.00 0.09 0.77 0.07 6.60 0.01⁎
Centrum semiovale 0.44 63.74 0.01⁎ 0.07 10.62 0.01⁎ 0.02 2.68 0.11
Prefrontal 0.18 17.04 0.01⁎ 0.01 0.57 0.45 0.01 0.97 0.33
Post parietal–occipital 0.36 45.68 0.01⁎ 0.11 16.91 0.01⁎ 0.02 3.63 0.06
Hippocampus 0.20 19.37 0.01⁎ 0.05 5.70 0.02⁎ 0.06 6.56 0.01⁎
Thalamus 0.21 20.74 0.01⁎ 0.05 5.16 0.03⁎ 0.01 0.82 0.37
Putamen 0.27 30.14 0.01⁎ 0.00 0.00 0.99 0.00 0.03 0.86
⁎ p b 0.05.
Table 1
Mean (SD) for MD of ROIs.
ROI MD
Control PKU
Splenium of the CC 0.79 (0.04) 0.79 (0.07)
Genu of the CC 0.86 (0.06) 0.82 (0.08)
Body of the CC 0.96 (0.08) 0.93 (0.13)
Optic radiation 0.85 (0.04) 0.85 (0.06)
Centrum semiovale 0.77 (0.03) 0.75 (0.04)
Prefrontal 0.77 (0.03) 0.78 (0.04)
Post parietal–occipital 0.81 (0.04) 0.77 (0.05)
Hippocampus 0.91 (0.03) 0.93 (0.05)
Thalamus 0.81 (0.03) 0.82 (0.04)
Putamen 0.76 (0.02) 0.76 (0.03)
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evidence suggests that it reaches maturity within the ﬁrst few years of
life in healthy children [36]. Thus, in comparison, children with early-
and continuously-treated PKU demonstrated substantially protracted
developmental changes in this tract.
In contrast, the white matter of the hippocampus and CC continues
to mature into the second decade of life in healthy individuals
[37–41]. Diffusion measures of the CC generally have greater noise
due to their close proximity with cerebrospinal ﬂuid [42], which could
mask subtle maturational changes. Nonetheless, we observed a
decrease in MD in the splenium and genu of the CC as a function of
increasing age for the PKU group but not the control group, suggesting
that this differential decrease is robust. With regard to the hippocam-
pus, decreases in MD have been shown to slow with increasing age for
healthy individuals [43], but in our sample of children with PKU MD
decreased to a greater extent than in healthy children.
It is also of interest to consider the possible neural mechanisms
underlying the well-established ﬁnding of poorer white matter
integrity in individuals with PKU compared with healthy controls.
Unfortunately, the possible mechanisms that have been suggested to
date (e.g., accumulation of intracellular debris [44]) remain speculative.
Further researchwith individualswith PKUand animalmodels of PKU is
clearly needed to elucidate the neural underpinnings of PKU-related
disruptions in white matter integrity.
5. Conclusions
Collectively, results from our study indicate that microstructural
white matter development is disrupted in children with early- and
continuously-treated PKU across a range of brain regions. Speciﬁcally,
there is an abnormal restriction of water diffusion in the white matter
that increases as children with PKU age. Although beyond the scope of
the current investigation, future research elucidating the impact of
disruptions in white matter development on functional outcomes
(e.g., neurocognitive, social, psychiatric) in children with PKU will be
crucial. In addition, longitudinal research will be important to investi-
gate potential differences in growth curves of MD between children
with PKU and healthy children.
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